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Abstract
Background: Large-scale expansion of myogenic progenitors is necessary to support the development of high-
throughput cellular assays in vitro and to advance genetic engineering approaches necessary to develop cellular
therapies for rare muscle diseases. However, optimization has not been performed in order to maintain the differentiation
capacity of myogenic cells undergoing long-term cell culture. Multiple extracellular matrices have been utilized
for myogenic cell studies, but it remains unclear how different matrices influence long-term myogenic activity in
culture. To address this challenge, we have evaluated multiple extracellular matrices in myogenic studies over
long-term expansion.
Methods: We evaluated the consequence of propagating mouse and human myogenic stem cell progenitors on
various extracellular matrices to determine if they could enhance long-term myogenic potential. For the first time
reported, we comprehensively examine the effect of physiologically relevant laminins, laminin 211 and laminin
521, compared to traditionally utilized ECMs (e.g., laminin 111, gelatin, and Matrigel) to assess their capacity to
preserve myogenic differentiation potential.
Results: Laminin 521 supported increased proliferation in early phases of expansion and was the only substrate
facilitating high-level fusion following eight passages in mouse myoblast cell cultures. In human myoblast cell
cultures, laminin 521 supported increased proliferation during expansion and superior differentiation with myotube
hypertrophy. Counterintuitively however, laminin 211, the native laminin isoform in resting skeletal muscle, resulted in
low proliferation and poor differentiation in mouse and human cultures. Matrigel performed excellent in short-term
mouse studies but showed high amounts of variability following long-term expansion.
Conclusions: These results demonstrate laminin 521 is a superior substrate for both short-term and long-term myogenic
cell culture applications compared to other commonly utilized substrates. Since Matrigel cannot be used for clinical
applications, we propose that laminin 521 could possibly be employed in the future to provide myoblasts for cellular
therapy directed clinical studies.
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Background
Satellite cells are the major effector cell responsible for
eliciting muscle regeneration. The satellite cell name was
conferred based on its identification on the periphery of the
myofiber characterized by very little cytoplasm and a
prominent nucleus. In this position, satellite cells re-
main in an inactive quiescent state characterized and
regulated by the transcription factor Pax7 [1]. Once
activated in response to muscle damage, satellite
cells up-regulate the transcription factor MyoD and
enter the cell cycle as transit-amplifying myoblasts
[2]. Once they reach sufficient numbers, myoblasts
exit the cell cycle, increase expression of myogenin,
and differentiate to form multinucleated myotubes
through the process of cellular fusion [3, 4]. These
myotubes form the building blocks for functional,
contractile muscle fibers.
In vivo, satellite cell activity is regulated by what is
referred to as the satellite cell “niche,” an extracellular
environment between the muscle fiber and the basal
lamina. In this location, extracellular matrix adhesion
proteins influence satellite cell activity in their quiescent
and activated states. Laminin 211, a heterotrimeric complex
composed of α2, β1, and λ1 chains, is a primary component
of the niche interacting with the satellite cell via the integ-
rin α7β1 complex [5]. Following activation, multiple extra-
cellular matrix (ECM) proteins are induced in the skeletal
muscle including fibronectin (FN), collagen 1, and collagen
3. Fibronectin binds to satellite cells by interaction with in-
tegrin α4β1 and integrin α5β1 complexes [6, 7]. Fibronectin
is up-regulated in the niche acting via Wnt7a and functions
to expand the stem cell pool of satellite cells and maintain
stem cell numbers [8, 9]. Laminin α5 is an additional
laminin isoform localized to regenerating myofibers
that is up-regulated specifically during murine skeletal
muscle regeneration and in human dystrophic muscle
[10, 11]. However, functional experiments have not
been performed to examine the satellite cell-laminin α5
relationship in detail. Although satellite cell laminin
α5-integrin studies have not been examined previously,
experimental studies have revealed that laminin α5
contains the greatest number of integrin-binding sites
that include those for α3β1 (2×), αVβ3, α6β1, α6β4, and
α7β1 [12–16].
The expansion of satellite cells and myoblasts is a critical
component for both neuromuscular drug discovery and cell
therapy applications. In both of these applications, methods
are required to provide large-scale expansion of myoblast
cells while maintaining high differentiation capacity and di-
minished spontaneous differentiation. Unfortunately how-
ever, comprehensive analysis of myoblasts has not been
performed after extended passaging in vitro; the majority of
experimental studies have been performed on satellite cells
and myoblasts that were freshly isolated due to the
challenges of expansion in vitro. Moreover, our attempts to
perform large expansion of satellite cell and myoblasts have
been challenged due to the progressive loss of differenti-
ation over time in culture (unpublished data). This chal-
lenge may hinder scaling of myogenic cells for multiple
applications including high-throughput screening and cell
therapy. One potential reason for this phenomenon may be
the use of biologically irrelevant cell substrates during myo-
blast expansion. For instance, myoblast are often cultured
on a variety of ECM substrates including laminin 111,
fibronectin, gelatin, collagen I, and Matrigel (MG) [17–21].
Although laminin is commonly utilized in myogenic cell
culture, the form commonly employed is laminin 111
which is composed of α1, β1, and λ1 chains; laminin struc-
ture is illustrated in Additional file 1: Figure S1. Laminin
111 is not expressed in adult skeletal muscle and differs
from laminin 211, the satellite cell niche component,
containing a different alpha chain [10]. In addition, other
substrates mentioned, MG, gelatin, and collagen I are not
associated with the satellite cell niche. Moreover, since
Matrigel is animal-derived, myogenic cells cannot be
expanded on Matrigel for clinical trials or future cell thera-
peutic applications. Nevertheless, while short-term testing
has been performed previously, long-term myoblast expan-
sion has not been compared between cellular substrates. In
this study, we present both short-term and long-term
expansion analysis of primary mouse and human myoblast
cultures on both commonly used substrates laminin 111
and MG, as well as previously untested but biologically
relevant laminin 211 (α2, β1, λ1) and laminin 511/521 (α5,
β1, λ1; α5, β2, λ1) substrates.
Methods
Isolation and culture of murine satellite cells
Primary murine satellite cells were isolated from the tibialis
anterior and quadriceps muscles from 12-week-old DBA/2J
male mice. Dissected muscles were minced with scalpel
blades and digested in DMEM/F12 (Life Technologies, 1:1
mixture) containing 2% collagenase II (Worthington Bio-
chemicals) and 1.2 U/ml dispase (Worthington Biochemi-
cals) with 2.5 mM CaCL2. Digestions were incubated at
37 °C for 1 h with trituration and mixing every 15 min. The
cells were filtered through 100 and 40-μM cell strainers
(BD). The cells were pelleted by centrifugation for 5 min at
300×g. The cells were resuspended in FACS staining buffer
(DMEM/F12/0.5% BSA/25 mM HEPES) and distributed in
200-μl aliquots into staining tubes. The cells were blocked
using anti-CD16/CD32 antibody (Ebioscience) at 1:100
dilution for 10 min on ice. The cells were stained with the
following antibodies on ice for 30 min: CD31-FITC (1:50,
Ebioscience, 390) CD45-FITC (1:50, Ebioscience, 30-F11),
PDGFRα-BV421 (1:40, BD, APA5), Sca1-BV605 (1:100, BD,
D7), and integrin α7 (1:400, Ablab, R2F2). The cells were
washed twice with sort buffer (HBSS/0.5% BSA/25 mM
Penton et al. Skeletal Muscle  (2016) 6:44 Page 2 of 16
HEPES) including centrifugation for 5 min at 300 g. Com-
pensation controls were prepared using Ultracomp beads
(Ebioscience). Single only bead controls were stained in
100 μl with 2 μl of each antibody for 15 min at room
temperature. The beads were washed once with sort buffer
and resuspended in sort buffer. Compensation was calcu-
lated using single-stained and unstained bead controls with
FACS DIVA compensation wizard. Gating was determined
by using fluorescence minus one plus isotype controls.
Dead cells were gated out using propidium iodide (Life
Technologies).
ECM coating and culture
Laminins including laminin 111, laminin 211, laminin 332,
laminin 411, laminin 421, laminin 511, and laminin 521 are
human recombinant isoforms obtained from Biolamina
(Sweden). Laminins are diluted at a concentration of 10 μg/
ml in HBSS with calcium and magnesium and coated over-
night at 4 °C. Growth factor reduced Matrigel (Corning)
was diluted 1:5 with DMEM/F12 media and thin coated by
covering plastic, removing excess, and drying Matrigel for
20 min at 37 °C.
For initial characterization, the cells were plated at a
density of 2000 cells per well in a 96-well format in
DMEM/F12/20% FBS/Primocin (Live Technologies/Invi-
voGen) with 10 ng/ml mouse FGF-2 (R&D). Media were
replaced after 5 days and refreshed every 3 days after-
wards. To induce differentiation at day 8, the media
were switched to differentiation media (DM), DMEM/
F12/5% HI-HS/Primocin, and maintained until day 11.
For long-term growth, the cells were plated at a density
of 10,000 cells per well in a 6-well format. The cells were
grown in growth media as previously described and
refreshed every 3–4 days with growth media and 10 ng/ml
FGF-2. Cells were split using Accutase and maintained on
the same substrate for six to eight passages. To assay differ-
entiation, the cells were split using Accutase and seeded in
a 96-well format at a density of 4000 cells per well. The
cells were grown in GM for 5 days, and then switched to
DM for an additional 5 days. For ECM substitution experi-
ments, the cells were thawed, expanded, and passaged twice
before analysis. At the second passage, the cells were trans-
ferred to a 96-well plate containing four of the ECM
substrates (laminin 111, laminin 211, laminin 521, and
MG). The cells were grown and differentiated similarly to
our previously mentioned long-term growth procedure.
Immunocytochemistry and imaging
Immunostaining was performed in black Corning 96-
well plates. For myosin heavy chain (MHC) staining, the
cells were fixed using Cytoperm/Cytofix for 15 min at
room temperature. The cells were rinsed twice and then
subsequently blocked using 10% HI-HS/0.1% Triton for
1 h at room temperature. The cells were stained with
MHC-Alexa488 antibody at 1:100 overnight at 4 °C. The
cells were rinsed four times with PBS and stained with
Hoechst to identify nuclei. Images were acquired using a
×10 objective on a Cellomics ArrayScan. Analysis was
performed using the Cellomics HCS Studio Version 6.5
software analyzing MHC-positive cells containing two or
more nuclei. The software algorithm used was the “myo-
tube formation” package using dynamic thresholding,
three sigma or isodata, for myotube identification.
For Pax7/MyoD staining, the cells were fixed using
foxp3/ki67 nuclear fixation buffer (Ebioscience) for 15 min
at room temperature. The cells were rinsed twice and
blocked with Block Aid (Life Technologies) for 1 h at room
temperature. Pax7 (1:50, R&D) and MyoD (1:50, 5F11,
Millipore) were coincubated overnight at 4 °C in Block Aid.
The cells were rinsed three times, and secondary antibodies
(donkey anti-mouse Alexa488, donkey anti-rat Alexa647;
1:200) were incubated for 1 h at room temperature. The
cells were rinsed four times and stained with Hoechst for
nuclei identification. Images were acquired using a ×20
objective on a Cellomics ArrayScan. Analysis was per-
formed using the nuclear colocalization algorithm (Cello-
mics HCS Studio 6.5) analyzing proportion of Pax7 or
MyoD-positive nuclei.
Integrin FACS analysis
Passage 8 mouse myoblasts were split using Accutase,
collected and centrifuged at 300×g for 5 min, and resus-
pended in FACS staining buffer. The cells were blocked
with FC block (BD biosciences) at 1:50 for 10 min on ice.
Afterwards, the cells were stained with the following PE-
conjugated antibodies: integrin alpha1 (BD 562115) at 1:40,
integrin alpha2 (Ebioscience 12-5971-81) at 1:40, integrin
alpha3 (R&D FAP2787P) at 1:10, integrin alpha4
(Ebioscience 12-0492-81) at 1:20, integrin alpha5 (BD
553930) at 1:40, integrin alpha6 (Ebioscience 12-0495-81)
at 1:200, integrin alpha7 (Ablab) at 1:200, integrin
alphaV (Ebioscience 12-0512-82) at 1:50, integrin
beta1 (Ebioscience 12-0291-81) at 1:20, integrin beta2
(Ebioscience 12-0181-81) at 1:20, integrin beta3
(Ebioscience 12-0611-81) at 1:40, integrin beta4 (R&D
FAB4054P) at 1:20, and integrin beta5 (Ebioscience
12-0497-41) at 1:20. The cells were stained for 30 min
on ice followed by two washes in FACS stain buffer.
The cells were resuspended in 300 μl of FACS buffer
and analyzed on the FACSAria II. Gating was set
according to negative unstained and isotype control
Rat IgG2a K-PE (Ebioscience 12-4321-81).
Human myogenic cell isolation
Post-mortem non-diseased skeletal muscle gracillis tissue
was obtained through Asterand. The muscle was trimmed
of fat and connective tissue. The tissue was minced for ap-
proximately 10 min. The tissue was digested using
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Collagenase II (Worthington Biochemicals) and Dispase
(Worthington Biochemicals), for approximately 75 min at
37 °C. Digestions were performed in gentleMACS™ Disso-
ciators. The tissue was pulsed every 15 min. Following
digestion, the cells were strained through 100-, 70-, and 30-
μM cells strainers (Miltenyi), respectively. The cells are
resuspended in approximately 200 μl of MACS stain buffer
(Miltenyi). The cells are stained for 1 h on ice with the fol-
lowing antibodies: CD11b-FITC (Miltenyi Biotec, Catalog
Number: 130-081-201), CD31-FITC (Miltenyi Biotec,
Catalog Number: 130-092-654), CD45-FITC (Miltenyi
Biotec, Catalog Number: 130-080-202), CD34-APC (BD
Biosciences, Catalog Number: 560940), and CD56-PE
(Miltenyi Biotec, Catalog Number: 130-090-755). After-
wards, the cells were rinsed twice and subsequently incu-
bated with anti-FITC microbeads (Miltenyi Biotec, 130-
048-701) for 30 min on ice followed by two washes. After-
wards, the cells were passed through a Miltenyi magnetic
depletion column. The column binds magnetically labeled
FITC+ cells (CD31, CD45, CD11b) while allowing FITC−
cells to flow through. The cells move passively through the
column into a collection tube. Afterwards, the cells were
centrifuged, resuspended in FACS buffer, and FACS sorted
(FACS ARIA II) for CD56+, CD34−, CD45−, CD31−, and
CD11b− cells. Myogenic cells were grown in growth media
DMEM/F12 (Gibco) supplemented with 20% FBS (Gibco)/
Primocin and 10 ng/ml human FGF2 (R&D). For differenti-
ation of human cells, cells were seeded at a density of
16,000 cells per well in a 96-well format. After 3 days, half
of the media was replaced with differentiation media
consisting of DMEM/F12 supplemented with 5% HS-HI
(Gibco) and Primocin. Afterwards, half of the media was
replaced every other day until day 11 when the cells were
fixed with Cytoperm/Cytofix (BD).
Statistics
Statistics for multiple comparisons were conducted using
one-way ANOVA with Bonferroni correction. Significance
is annotated as less than .05 (*), less than .01 (**), less than
.001 (***), and less than .0001 (****). All comparisons were
conducted using laminin 521 as control. Significance for
myotube nuclei distribution was determined using linear
regression. Statistical calculations were conducted using
Graphpad Prism 6.
Results
ECM influences myogenic potential
To compare the activity of freshly isolated mouse satellite
cells, we FACS sorted Integrinα7+/PDGFRα–/Sca1−/CD31
−/CD45− cells (Additional file 2: Figure S2) and plated on
ECM substrates including laminin 111, laminin 211,
laminin 332, laminin 411, laminin 421, laminin 511, laminin
521, gelatin, and growth factor reduced MG (Fig. 1a). We
observed a striking increase in proliferation resulting in a
three- to fourfold increase in cell number on laminin 511,
laminin 521, and MG compared to all other substrates
(Fig. 1a, c). In addition, the cells expanded on laminin 511,
laminin 521, and MG showed dramatically enhanced differ-
entiation as quantified by MHC-positive area (Fig. 1b). On
the other hand, cells on laminin 111 differentiated moder-
ately while cells on laminin 211, laminin 332, laminin 411,
and laminin 421 differentiated poorly (Fig. 1a, b). Addition-
ally, myotubes formed on laminin 521 and MG visually
appeared to be wider in appearance and overall more
robust. Cells differentiated on laminin 521 appeared to be
more organized in comparison and more mature as we
noted the nuclei in laminin 521 cultures evenly spaced and
distributed while MG myotubes nuclei had a clustered
appearance and myotubes appeared less organized. To
extend these results beyond the Dba mouse model, we re-
peated our differentiation experiments on C57/BL6 and
C57/BL10 satellite cells. Consistent with the Dba satellite
cell results, cellular differentiation is consistently increased
on laminin 511, laminin 521, and MG compared to all
other substrates (Fig. 1d, e).
While satellite cells typically have strong differenti-
ation potential when freshly isolated, no study to our
knowledge has evaluated a variety of ECMs to expand
satellite cell-derived myoblasts to maintain their stem
cell and differentiation potential after long-term culture.
Therefore, we selected laminin 111 and MG due to their
common usage in the literature, as well as laminin 211
and laminin 521 due to their expression in vivo. Add-
itionally, we selected laminin 521 over laminin 511 due
to the observed performance benefit in our short-term
study in Fig. 1. Dba cells were grown for six to eight
passages and then assayed for proliferation and differenti-
ation. Similar to our short-term results, we found signifi-
cant differences in differentiation among different ECMs,
and these differences appear to be amplified over the long
term. Laminin 111 displayed significant proliferation but
differentiated minimally (Fig. 2a, d). While the myotubes
formed on laminin 111 were fairly large in size, the majority
of the cells in culture were negative for MHC (Fig. 2c).
Laminin 211 on the other hand performed similarly to the
fresh analysis from Fig. 3 where cells expanded at a very
slow rate and failed to differentiate (Fig. 2a, d). Laminin 521
and MG both were the only substrates that supported
extensive myogenic differentiation, as assayed by MHC-
positive area after culture in DM (Fig. 2a, d). However,
while laminin 521 and MG have similar MHC area percent-
ages, cells on laminin 521 form more multinucleated myo-
tubes, defined as myotubes containing two or more nuclei,
compared to cells on MG (Fig. 2c). Moreover, MG cells up-
regulate MHC but fail to fuse significantly remaining in a
myocyte stage resulting in approximately 70% of the cells
expressing MHC but only containing one nucleus (Fig. 2c).
On the other hand, 70% of laminin 521 assayed cells
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AB C
D E
Fig. 1 Laminin 521/511 and MG support superior differentiation and proliferation in freshly isolated satellite cells. a Differentiation of freshly isolated
satellite cells (Dba/2J), myosin heavy chain (green), and Hoechst (blue). b Quantification of differentiation via mean MHC calculated area (Dba/2J). c
Quantification of total nuclei per well via Hoechst nuclei count (Dba/2J). Quantification of differentiation via MHC calculated area from freshly isolated
C57/BL6 (d) and C57/BL10 (e). Error bars represent means ±S.D. Scale bar represents 200 μM. N= 3 biological replicates per group. Statistical significance
was determined by one-way ANOVA with Bonferroni correction. Significance is annotated as less than .05 (*), less than .01 (**), less than .001 (***), and less
than .0001 (****). All comparisons were conducted using laminin 521 as control
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contain two or more nuclei (Fig. 2c). To further quan-
tify myogenic differentiation, we performed an in-
depth multi-nucleation index to quantify the number
of nuclei per myotube proportional to the total nuclei
of myotubes on laminin 111, laminin 521, and MG.
We determined at both passage 6 and passage 8 that
laminin 521 myotubes contained increased propor-
tions of nuclei per myotube compared to MG and
laminin 111 (Fig. 2e, f ). Strikingly, laminin 521 myo-
tubes contained a broad increase in the proportion of
nuclei per myotube over the entire distribution of
myotubes ranging from two to ten nuclei per myo-
tube (Fig. 2e, f ). Overall, these results reveal that lam-
inin 521 may be a superior substrate for expanding
myogenic cell cultures over long-term passage while
maintaining excellent differentiation.
In order to confirm laminin 521 activity on additional
background strains over long-term passaging, we cultured
C57BL/6J (BL6) and C57BL/10ScNJ (BL10) primary myo-
blasts to eight passages and assayed for differentiation per-
formance. Similar to previously discussed findings, laminin
521 expanded myoblasts from BL6 and BL10 strains
robustly differentiated into multinucleated myotubes at a
significantly higher efficiency compared to laminin 111 and
laminin 211 (Fig. 3a, b). MG performance varied substan-
tially between BL6 and BL10 expanded cells; while BL6 cells
exhibited poor differentiation, BL10 cells exhibited a similar
amount of MHC area per nuclei compared to laminin 521.
Multi-nucleation indexes were next calculated for BL6 and
Bl10 cells on each of the four substrates including laminin
111, laminin 211, laminin 521, and MG. In BL6 cultures,





Fig. 2 Laminin 521 is the only substrate capable of maintaining differentiation after eight passages in Dba satellite cell-derived myoblasts. a Quantification
of differentiation via MHC area calculation. b Quantification of total nuclei per well via Hoechst nuclei count. Statistical significance was determined by
one-way ANOVA with Bonferroni correction. N = 3 technical replicates per group from one biological sample. Significance is annotated as less than .01
(**), and less than .0001(****). All comparisons were conducted using laminin 521 as control. c Differentiation index, calculation of proportion of MHC+
myotubes containing two or more nuclei, MHC+ myocytes containing a single nuclei, and proportion of MHC− cells. d Immunostaining for MHC
(green) and Hoechst (blue). Scale bar represents 200 μM. N = 4 wells per group. e, f Multi-nucleation index quantifying the number of
nuclei per myotube as a proportion of total nuclei at passage 6 (e) and passage 8 (f). Statistical significance for e, f was determined by
linear regression. The distribution of laminin 521 was found to be significantly different, p < .001, compared to laminin 111 and MG
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distribution towards myotubes containing five or more
nuclei while laminin 111 and MG cultures were enriched
for myotubes containing one to four nuclei in MHC-
positive cells (Fig. 3c). In addition, laminin 111 and MG
contained a significantly higher number of undifferentiated
MHC-negative cells in BL6 cultures (Fig. 3c). In BL10
cultures, laminin 521 and MG performed similarly regard-
ing myonuclei distribution although laminin 521 contained
approximately 10% increased proportion of myotubes
containing 10 or more nuclei and laminin 521 contained
approximately 20% reduced proportions of MHC-negative
cells (Fig. 3d). Overall, these results confirm laminin 521
promotes the most optimal and consistent differentiation of
long-term passaged myoblasts across background strains
compared to the other substrates tested. Moreover, while
MG differentiated well during BL10 expansion, both Dba
and BL6 expansions lacked differentiation suggesting that
laminin 521 expansion may provide more consistent differ-
entiation following expansion.
Initial expansion on ECM dictates differentiation on other
substrates
To determine the utility of using laminin 521 for cell
types already expanded on substrates other than laminin
521, we performed a substrate substitution experiment
evaluating our previously isolated primary mouse myo-
blasts on each of the other substrates in our study. Dba
cells expanded on laminin 521 show robust differentiation
when transferred to any of the substrates tested here
including laminin 111, laminin 211, and MG (Fig. 4a, b). In
comparison, while cells maintained on laminin 521 demon-
strated the highest differentiation performance, cells moved
from laminin 521 to other substrates (laminin 111, laminin
211, and MG) showed a small reduction in differentiation
(Fig. 4a, b). Additionally, we observed a lag in the initial
proliferation when laminin 521 cells were transferred to
other substrates, although cultures did gradually increase
proliferation over time (data not shown). The cells
expanded on all other substrates, including laminin 111,
laminin 211, and MG and failed to differentiate signifi-
cantly, both on their original substrates and when moved to
other substrates (Fig. 4b). These results reveal that laminin
521 expanded myoblasts demonstrate superior propensity
to maintain differentiation and reveal unique, broad, sub-
strate transfer compatibility.
Next, we repeated the ECM switching experiments in
our long-term BL6 and BL10 cultures to determine if we
observe similar substrate compatibility on different
A B
C D
Fig. 3 Laminin 521 supports robust differentiation in C57/BL6 and C57/BL10 backgrounds after eight passages. Quantification of differentiation
via MHC area calculation in proportion to total nuclei for BL6 (a) and BL10 (b). c, d Multi-nucleation index quantifying the number of nuclei per
myotube as a proportion of total nuclei in BL6 (c) and BL10 (d) cultures at passage 8. Statistical significance for a, b was calculated using one-way
ANOVA with Bonferroni correction. N = 3 technical replicates per group. Significance is annotated as less than .001 (***). All comparisons were
conducted using laminin 521 as control. Statistical significance for c, d was calculated using linear regression. The distribution of laminin 521 was
found to be significantly different, p < .001, compared to laminin 111 and MG
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backgrounds. In BL6 and BL10 cultures, the cells
expanded on laminin 111 increased their differentiation
efficiency when moved to both laminin 521 and MG
(Fig. 5a, b). However, laminin 211 expanded BL6 and
BL10 cells showed the most significant increase in differ-
entiation on laminin 521 (Fig. 5a, b). Interestingly, lam-
inin 521 expanded BL6 cells moved to laminin 211 and
MG differentiated similarly to control but transferring to
laminin 111 showed a marked decrease in differentiation
(Fig. 5a). Moreover, laminin 521 expanded BL10 cells
moved to laminin 111, and MG showed similar differen-
tiation compared to the control while cells moved to
laminin 211 displayed a drop in differentiation (Fig. 5b).
BL6 MG expanded cells moved to laminin 521 for differ-
entiation maintained similar performance compared to
the control while there was a significant reduction in
differentiation when cells were transferred to laminin
111 or laminin 211 (Fig. 5a). In BL10 MG expanded
cultures, the cells transferred to laminin 111 and laminin
211 differentiated similar to the control but the cells
moved to laminin 521 displayed a decrease in differenti-
ation (Fig. 5b). Overall, these results demonstrate that
both laminin 521 and MG can increase the differentiation
performance of myogenic cells previously expanded on
different matrices. However, we observe significant dif-
ferences in the compatibility and performance gains or
losses that vary with the specific substrates and back-
ground used.
Expanded myoblasts express similar myogenic markers
across matrices
Due to the large differences observed in myogenic cell
performance, we performed a set of control experiments
to rule out the presence of contaminating non-myogenic
cells in our primary mouse myoblast cell cultures. FACS
staining revealed 99% of cells stained positive for integrin
α7 (Fig. 6a) while there were no detectable PDGFRα- or
CD31-positive cells present (data not shown) suggesting
that our cultures were homogenous for myogenic cells.
Subsequently, we immunostained cells from passage 6,
during the expansion phase in growth medium, to deter-
mine the expression of Pax7 and MyoD to assess if
changes in their expression or intensity may explain the
dramatic difference in myogenic activity on different
ECMs (Fig. 6b, c). We observed similar proportions of
Pax7 and MyoD positively stained cells on each substrate
(Fig. 6b). Protein staining intensity level varied minimally
for Pax7 and MyoD expression (Fig. 6c). We observed sta-
tistically significant differences for Pax7 expression level
changes; however, changes were small ranging around
±50% compared to laminin 521 (Fig. 6c). MyoD expres-
sion levels were consistent except for a reduction in
expression level in laminin 211 cultures. Interestingly,
Sca1 expression was found to be present in a significant
proportion of cells cultured on laminin 111 and laminin
211 but was absent in cultures maintained on laminin 521
and MG (data not shown). These results agree with
A
B
Fig. 4 Expansion of Dba satellite cell-derived myoblasts on laminin 521 maintains differentiation when transferred to alternate substrates. Passage
8 myoblasts were transferred from laminin 521 to alternate substrates (a) but still show robust differentiation visualized by MHC expression (green)
and Hoechst (blue). MHC area was quantified for all the different expansion and differentiation conditions (b). Laminin 521 expanded cells
differentiated on all substrates. Error bars represent ±S.D. Scale bar represents 200 μM. Statistical significance was determined by one-way
ANOVA with Bonferroni correction. N = 10 technical replicates from one biological sample. Significance is annotated as less than .01 (**),
less than .001 (***), and less than .0001 (****)
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previous studies in which case Sca1 expression on myo-
blasts was associated with cells exhibiting poor differenti-
ation [22]. These results suggest that Sca1 may be a
marker associated with differentiation-deficient myogenic
cells; however, this will require further study.
FACS profiling reveals variation in integrin expression
Integrin receptor signaling plays many critical roles
during myogenesis. Since laminins and components of
MG activate many of their functions via integrin
receptors, we hypothesized that our observed differ-
ences in long-term culture may be caused by shifts in
integrin expression on different ECMs. Previously ex-
panded Dba mouse cells were assayed at passage 8 in
growth conditions on each ECM (laminin 111, laminin
211, laminin 521, and MG) by FACS staining using
integrin α1–7, integrin αV, and integrin β1–5 anti-
bodies (Table 1).
Close to 100% of cells grown on all substrates expressed
integrin α7 and β1 (Table 1). On the other hand, only a
small proportion of cells expressed α1 (10–20%) while less
than 5% of cells on any substrate expressed α2 or β5
(Table 1). Meanwhile, the remaining integrins showed
some degree of heterogeneous expression across sub-
strates. Expression of α4, α5, β2, and β4 was similar and
heterogeneous on most substrates, with the exception of
the high expression of β2 on laminin 111 and MG, and an
absence of expression of β4 on laminin 211 and elevated
expression on MG (Table 1). Most intriguingly, integrin
α3 was expressed by a larger proportion of cells, approxi-
mately 30%, on cells expanded on laminin 521 and MG
while it was expressed by less than 10% on cells expanded
A
B
Fig. 5 Long-term expanded BL6 and BL10 myoblasts transferred to alternative substrates show variable responses. Differentiation was quantified
by calculating MHC area in proportion to total nuclei for BL6 (a) and BL10 (b) passage 8 myoblasts. Statistical significance was determined by
one-way ANOVA with Bonferroni correction. N = 6 technical replicates. Significance is annotated as less than .05 (*), less than .01 (**), less than
.001 (***), and less than .0001 (****)
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on all other ECMs (Table 1). In addition to population
changes, we also observed variations in mean fluorescent
intensities for a subset of integrins including integrin α3,
integrin α5, integrin α6, integrin α7, integrin β2, and
integrin β4 (Table 2). For example, integrin α3 showed ele-
vated expression on laminin 521 expanded cells. Integrin
α5 showed elevated expression in cells grown on laminin
111 and laminin 211, while integrin β2 had highest
expression on laminin 111 (Table 2). Integrin α6 expres-
sion was increased dramatically on MG cultured cells
while integrin α7 was expressed higher on MG cultured
cells and, to a lesser extent, on laminin 521 cells (Table 2).
Lastly, integrin β4 showed very little expression on laminin
211 cells while it was up-regulated in MG cultured cells
(Table 2). Taken together, these results suggest that both
the proportion of cells expressing each integrin and the
expression level of integrins varies with different ECM
matrices. Moreover, due to the complexity observed here,
there are likely multiple mechanisms contributing to the
different characteristics of cells expanded on different
ECMs.
Laminin 521 supports enhanced human myoblast
expansion and differentiation
In an effort to determine if the result obtained with the
mouse model translated to humans, we identified a
source of freshly isolated human muscle and performed
a similar evaluation. Human satellite cells were isolated
A
B C
Fig. 6 Expanded cells are purely myogenic and exhibit similar Pax7/MyoD expression. a Cells display greater than 99% positive expression of satellite
cell/myoblast marker integrin α7—PE. Twenty thousand cells were analyzed for each substrate. b, c Cells on all substrates maintain similar expression
regarding proportion of positive cells and staining intensity for both Pax7 and MyoD. N = 6 technical replicates for each group from one biological
sample. Significance was determined by one-way ANOVA with Bonferroni correction. Significance is annotated as less than .05 (*), and less than .001
(***). All comparisons were conducted using laminin 521 as control
Table 1 Integrin FACS profiling on passage 8 Dba cells
111 211 521 MG
α1 22.13 12.45 25.95 19.61
α2 0.55 0.19 2.63 5.41
α3 5.59 12.73 30.35 34.41
α4 67.53 42.86 67.64 90.98
α5 99.05 92.36 80.46 93.86
α6 78.81 67.66 62.4 96.61
α7 98.92 97.4 94.48 99.84
β1 99.01 99.07 96.04 99.95
β2 88.11 53.92 62.3 82.72
β3 69.59 67.05 44.08 57.48
β4 35.58 1.52 44.8 85.72
β5 0.2 0.17 0.57 3.94
Values represent % cells positive for selected integrins on Dba passage cells
Table 2 Mean fluorescent intensity on passage 8 Dba cells
111 211 521 MG
α3 2436 2848 3704 2167
α5 344,468 377,705 111,181 46,012
α6 4418 4316 5556 43,222
α7 21,973 23,195 44,471 73,179
β2 25,736 4909 5829 5772
β4 1890 601 3217 7345
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from the gracillis muscle obtained from a post-mortem
patient lacking diagnosed skeletal muscle disease. CD56
+/CD31−/CD45−/CD11b− satellite cells were isolated
using a dual MACS/FACS approach (Fig. 7a). The cells
were initially expanded on each of the following
substrates: laminin 111, laminin 211, laminin 521, and
MG. Within the first week of growth, we observed a dra-
matically increased growth rate with cells expanded on
laminin 521 compared to all other substrates (Fig. 7b).
Additionally, laminin 211 appeared to display a lag in
cell growth compared to other substrates, similar to our
earlier satellite cell findings in mouse (Fig. 7b).
Since our mouse studies revealed unexpected expansion
and differentiation effects on long-term culture of satellite
cell-derived myoblasts on specific substrates, we next
performed a similar study on our newly generated human
myogenic cells. Human myoblasts expanded at a faster rate
on laminin 521 compared to other substrates following five
passages (Additional file 3: Figure S3). In addition, the
human cells displayed the highest amount of differentiation
on laminin 521 and MG, followed by moderate differenti-
ation on laminin 111 and poor differentiation on laminin
211 (Fig. 8a, b). In addition, myotubes formed on laminin
521 and MG appeared to be hypertrophic due to an
increased amount of MHC area staining in proportion to
myotube nuclear count (Fig. 8c). Importantly, we observed
differentiated myotubes maintained better attachment on
laminin 521 compared to MG, in which case we observed
larger variability on MG due to myotube detachment.
Laminin 211-differentiated cultures performed poorly,
A
B
Fig. 7 FACS isolation and early growth of human satellite cells. a FACS isolation for human satellite cells selecting for granularity (SSC × FSC),
singlet selection (FSC-W × FSC-H, SSC-W × SSC-H), live/dead (propidium iodide), CD31−/CD45− (FITC), CD34− (APC), and CD56+ (PE). b Laminin
521 shows a clear growth advantage over all other tested substrates. Scale bar represents 300 μM
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similar to the observations with the mouse cultures. This
resulted in a majority of cells staining negative for MHC
expression and a very small MHC area value (Fig. 8b, c).
Laminin 111 differentiated well but only reached approxi-
mately half of the MHC area compared to laminin 521 or
MG cultures (Fig. 8b).
Discussion
A vast amount of research has been performed on satellite
cell/myoblast biology and myogenesis over the past 50
years. This work has yielded an enormous depth of know-
ledge encompassing wide number of molecular regulators
ranging from transcription factors, signaling molecules,
and ECM proteins. Despite this progress, there remains a
significant disparity in work to support cell therapy and
drug discovery efforts with satellite cells and myoblasts. A
number of challenges have remained unsolved; how to
scale up a relatively small number of skeletal muscle
precursors into hundreds of millions or billions of cells for
high-throughput drug screening or stem cell engraftment.
In order to perform drug discovery in relevant models
derived from stem cells isolated from patients, it is critical
that the cells maintain the expansion and differentiation
potential of the primary cell type. In addition, while Matri-
gel has become a very common ECM for satellite cell and
myoblast culture, it is critical to establish an alternative
ECM substrate which is animal-free and non-xenogeneic
for cell therapy development and clinical trials. Given that
target cells for assays addressing the majority of neuro-
muscular disease are multinucleated and differentiated
myotubes and not transit-amplifying myogenic cells, it is
critical that culture conditions support the ability of the
expanded primary cells to differentiate effectively into
myotubes. Many of the common reagents used for basic
biology research, particularly ECM substrates, have not
been tested in long-term experiments with multi-passage
myogenic cell cultures. Because of this disparity, it is cru-
cial to perform culture testing over the long term; doing
so will help advance both basic muscle research and accel-
erate drug development advancement by broadly improv-
ing myogenic cell performance. Here, we provide the first
comprehensive analysis detailing the proliferation and
differentiation performance of different ECM’s on both
mouse and human myogenic cells in short-term and long-
term expansion.
The studies reported here demonstrate that the optimal
ECM substrates for large-scale myogenic expansion are
those that incorporate laminin α5, a previously underap-
preciated isoform of the laminin family in skeletal muscle.
While laminin α5 is normally expressed during regener-
ation in both Ctx mouse models and DMD tissue, no
study has been performed regarding its utility in in vitro
myogenesis studies [10]. Here, our mouse studies show
laminin 521 (α5, β2, λ1) supports superior myoblast
performance in vitro by facilitating impressive prolifera-
tion and maintenance of differentiation after eight pas-
sages and approximately a 5000-fold expansion. These
results indicate that laminin 521 may be a more ideal
substrate for large scale-up applications, by helping to
minimize the loss in differentiation potential over time. In
our studies, mouse myogenic cells expanded on laminin
111 progressively lost their ability to up-regulate MHC
while MG-expanded cells entered a state whereby they
entered a myocyte stage expressing MHC but then fail to
A
B C
Fig. 8 Laminin 521 supports improved human myogenic cell differentiation. a Cells expanded on laminin 521 and MG show significant differentiation
after five passages in vitro, MHC (green), Hoechst (blue). b MHC area quantification shows increased differentiation in laminin 521 cultures and better
stability compared to MG. c MHC/nuclear ratios show laminin 521 and MG differentiated cells display hypertrophy. Error bars represent ±S.D. Scale bar
represents 200 μm. N = 10 technical replicates from one biological source. Significance was determined by one-way ANOVA with Bonferroni correction.
Significance is annotated as less than .05 (*), less than .01 (**), and less than .0001 (****). All comparisons were conducted using
laminin 521 as control
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fuse. In addition to the mouse study presented here, we
have performed an analysis of freshly isolated mdx/BL10
cells, and we observed a very similar pattern with laminin
521 outperforming laminin 111, laminin 211, and MG in
differentiation (Additional file 4: Figure S4). Furthermore,
we have encountered difficulty in expanding mdx/BL10
cells on laminin 111 while we have not encountered these
issues on laminin 521 (data not shown). Importantly, our
findings translate to human myogenic cell culture as our
human cells perform optimally on laminin 521 showing
superior proliferation and differentiation to all other sub-
strates tested. Taken together, our results demonstrate
laminin 521 as an optimal substrate for myoblast expansion
while demonstrating translatability across several mouse
backgrounds (Dba/2J, C57/BL10, C57/BL6), human cells,
and disease states (mdx/BL10).
While our results strongly support laminin 521 as a
superior myoblast culture matrix, additional studies will
be required to further evaluate the effects of laminin 521.
Particularly, additional study will need to be conducted
with additional human samples to confirm that laminin
521 is broadly beneficial across multiple human myogenic
progenitors. We have directly measured the amount of
protein coating among the different substrates used in this
study and find only a minimal difference between the dif-
ferent laminins and gelatin used in our study (Additional
file 5: Figure S5). Matrigel resulted in an increased amount
of protein compared to other substrates (Additional file 5:
Figure S5). Despite these differences in coating amounts,
we do not observe significant differences in cellular
adherence in either freshly isolated cells (Additional
file 6: Figure S6A) or long-term passaged cells (Add-
itional file 6: Figure S6B). We have observed however
that the presence of high concentrations of calcium
and magnesium, as found in HBSS and PBS containing
calcium and magnesium, are critical for laminin coating
function. The inclusion of calcium and magnesium during
laminin coating is not commonly included in many of the
commercial vendor protocols, despite the critical roles of
calcium and magnesium in laminin signaling.
The observed benefits of laminin 521 are likely due to the
larger number of integrin binding sights on laminin α5 in-
cluding unique binding sites for integrin α3, αV, and α6β4
not present in other laminin isoforms [12–15]. Laminin
521 can therefore be seen as a richer substrate capable of
interacting with six integrin binding sites (α3β1 (2×), αVβ3,
α6β1, α6β4, α7β1), compared to four binding sites in
laminin 111 and MG (α1β1, α2β1, α6β1, α7β1) [12, 15].
The converse also may be true for laminin 211; it may fail
to stimulate a high level of proliferation due to the presence
of only three integrin-binding sites (α1β1, α2β1, α7β1) [12].
Our studies have shown that a greater proportion of cells
express integrin α3 on laminin 521 and MG expanded cells
compared to all other substrates (Table 1). Multiple studies
show that integrin α3 is a critical component during myo-
genic cell differentiation [23, 24]. However, our results also
suggest that integrin α3-laminin α5 interaction may not be
critical for differentiation since cells moved from laminin
521 to other substrates maintain the ability to differentiate,
even on the minimalistic laminin 211. While our studies
show MG expanded cells turn on the differentiation pro-
gram through up-regulation of MHC, there is a deficit in
myoblast fusion in long-term cultures. We observed an
increased expression level of integrin α7 in both laminin
521 and MG cultures (Fig. 6). Since integrin α7 increases
myoblast mobility and is dramatically increased during
myogenic differentiation, increased expression of integrin
α7 in our cultures is a possible mechanism promoting
enhanced differentiation. These findings may suggest that
expression of integrin α3 and high expression of integrin
α7 assist cells in initiating the differentiation program but
additional mechanisms are likely responsible for the differ-
ence in myotube formation between cells expanded on
laminin 521 and MG. Other key differences observed in-
cluded decreased expression level of integrin α5 on laminin
521 expanded cells and increased proportions of cells
expressing integrin β2 and integrin β4 in MG cultures.
Studies have shown expression of integrin α5 regulates
myogenesis by favoring expansion and inhibiting differenti-
ation, thus reduced integrin α5 on laminin 521 expanded
cells may contribute to the maintenance of differentiation
in the long term [11, 25, 26]. Overall, while our studies re-
veal multiple differences in the expression of integrins fol-
lowing long-term culture, however, there appears to be
some long-lasting effects of growth on each of the ECM
substrates that is poorly understood and cannot be ex-
plained merely by mapping integrin-ECM binding interac-
tions. It will be critical in future experiments to use integrin
inhibition to determine which integrins are critical for
maintaining differentiation ability in myogenic cultures.
While we acknowledge our integrin study is limited due to
the inclusion of only the Dba mouse strain, most import-
antly, our findings encourage future investigation of integ-
rin expression across backgrounds, species, and passage
time points in culture. It will be crucial to expand on these
findings as we expect integrin expression to vary between
biological samples and conditions.
This study significantly demonstrates that various sub-
strates are not created equal when they are employed for
the expansion of myoblasts in vitro. While the performance
of laminin 521 is impressive, there may be room for
improvement by combining additional ECMs with laminin
521. First, it will be important to analyze the combination
of laminin 521 with laminin 111 and laminin 211 to deter-
mine if there is any potential synergism. While laminin 521
fared the best in differentiation after scale-up, spontaneous
differentiation was still present at a low level. Collagen VI
has been described as a critical mediator of stem cell
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renewal in the satellite cell niche suggesting it may prevent
progression into differentiation [27]. Considering this, col-
lagen VI in combination with laminin 521 may reduce the
spontaneous differentiation during expansion, at which
time collagen VI could be removed to induce differenti-
ation. ECM stiffness is a critical regulator balancing myo-
genesis towards proliferation or differentiation [28–32].
Combining laminin 521 with MG or a hydrogel may pro-
vide increased performance in both proliferation and/or
differentiation by providing a method to customize stiff-
ness of the substrate to optimize both proliferation and
differentiation conditions. It will be important in future
studies to titrate laminin 521, which will affect both
substrate stiffness and geometry of the laminin matrix,
both of which may significantly affect proliferation and
differentiation.
Two of the most popular myogenic matrices routinely
employed in stem cell biology are MG and laminin 111;
however, neither of these substrates is endogenous to the
satellite cell niche. Additionally, MG is a highly variable
substrate isolated from mouse EHS tumors containing over
14,000 peptides resulting in experimental variability and
decreased reproducibility [33]. In fact, even growth factor
reduced MG, as used in this study, contains over 9000 pep-
tides and significant variation as high as 50% from batch to
batch has been observed which makes cell culture perform-
ance inconsistent [33]. The laminin α1 chain contained in
both MG and laminin 111 is absent from adult skeletal
muscle in both resting and regenerating conditions and is
only expressed in a small stage of developmental myogen-
esis [10, 34, 35]. This discrepancy has by and large gone
unverified with the assumption that laminin 111 and
laminin 211 share redundant functionality. For instance,
pre-clinical animal studies have been performed injecting
laminin 111 into dystrophic mice despite the lack of α1 in
the muscle [36]. However, these results are controversial
since follow-up transgenic laminin 111 studies show no
benefit in the mdx model [37]. Our results show for the
first time that there are significant functional differences be-
tween the laminin α1 and α2 chains. While α1 supports
moderate proliferation and differentiation in our studies, α2
tends to limit proliferation and supports differentiation
poorly. Considering this in combination with our results,
laminin 511 or laminin 521 supplementation/overexpres-
sion may be superior therapeutically for muscular dystro-
phies including DMD since they contain the beneficial
integrin α7 binding site similar to laminin 211 and laminin
111, but laminin 511 and laminin 521 may additionally
boost the regenerative response. One caveat for potential
intramuscular laminin α5 injection or overexpression is that
laminin 521 is normally expressed at neuromuscular junc-
tions while laminin 511 surrounds regenerating myofibers;
thus, in vivo comparison studies between laminin 511 and
laminin 521 will be crucial [10].
The studies presented here suggest that the laminin 521
findings may be translatable to additional technologies
including cell therapy-engraftment technology and iPS
skeletal muscle differentiation. In recent years, cell therapy
for the muscular dystrophies has lost favor due to the
inability to generate sufficient numbers of engraftment-
capable myoblasts for transplantation. In the early 90s,
while cell therapy was a highly promising technology due
to newly developed myoblast cell culture, human myoblast
trials were a failure due to the inability of the in vitro prop-
agated cells to efficiently engraft or provide functional
muscle strength recovery [38–41]. Subsequent mouse
studies demonstrated that freshly isolated myogenic cells
are highly efficient at engrafting, but over time, the culture
engraftment potential dramatically falls [42]. Historically,
cell therapy and engraftment experiments commonly
utilize gelatin, MG, or laminin 111 as expansion substrates
[21, 43–46]. As demonstrated in the results presented in
this report, these are not the best substrates for in vitro
scale up of pre-implanted cells. Our studies suggest that
laminin 521 may provide a better option for the scale-up
of cells for cell therapy since we demonstrate that laminin
521 is the only substrate in our studies capable of main-
taining differentiation over an extended expansion period.
Studies are currently underway to analyze the engraftment
potential of mouse myoblasts expanded on varying sub-
strates including laminin 521. The differentiation of
skeletal muscle differentiation from iPSCs is currently not
well defined even though a number of reports have been
published using protocols with varying techniques and
ECM substrates [47–50]. Since laminin α2, laminin α4,
and laminin α5 are expressed during muscle development,
it will be important to test these substrates in iPSC studies
to determine the optimal ECM induction substrate [10, 11].
Additionally, while multiple protocols exist to produce
iPSC-derived myogenic cells, iPSC-generated skeletal
muscle cell expansion has not been well characterized
examining performance after large scale-up of the gener-
ated cells. In this avenue, laminin 521 may provide a signifi-
cant advantage in maintaining iPSC myogenic cells in a
differentiation-competent state while the cells are expanded
into large numbers for drug screening and cell therapy
applications.
Conclusions
Laminin 521 represents a new high performance, bio-
logically relevant matrix for superior muscle cell per-
formance in vitro. Laminin 521 supports generation of
larger myotubes and higher amounts of nuclei per myo-
tube compared to all other substrates with the exception
of Matrigel. However, while laminin 521 matches the
performance of Matrigel, it also provides more consistent
and reliable differentiation over long-term culture. Particu-
larly, laminin 521 represents an excellent substrate for cell
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therapy development and clinical trials due to its human
origin; Matrigel on the other hand is not compatible with
clinical trials or cell therapy applications in humans.
Laminin 521 appears to increase differentiation poten-
tially without altering the traditional Pax7/MyoD para-
digm; it is likely that laminin 521 is providing novel cell
regulation not previously appreciated. It may be benefi-
cial to integrate laminin 521 into currently established
techniques in muscle biology research to achieve syner-
gism with other matrix proteins or technologies. In con-
clusion, laminin 521 extends the use of isolated primary
cells and is likely to enhance many applications requiring
large growth expansion such as drug discovery, genetic
engineering, and cell therapy.
Additional files
Additional file 1: Figure S1. Laminin chain structure. Laminins are
heterotrimeric complexes annotated in the order of α, β, and λ chains.
Examples are laminin 111 = α1, β1, and λ1 and laminin 521 = α5, β2,
and λ1.
Additional file 2: Figure S2. FACS sort of DBA/2J satellite cells. Cells were
sorted for granularity (SSC × FSC), singlet selection (FSC-W× FSC-H, SSC-W×
SSC-H), live/dead (propidium iodide), CD31−/CD45− (Percp-eFluor710),
Pdgfrα−/Sca1− (BV421/BV605), and integrin α7+ (PE).
Additional file 3: Figure S3. Laminin 521 promotes increased human
myogenic cell proliferation. Cells were expanded on laminin 111, laminin
211, laminin 521, or growth factor reduced Matrigel for 5 passages. For
proliferation analysis, cells were seeded at a density of approximately
1500 cells per well and incubated for 2 days. Afterwards, cells were fixed
and nuclei counts were performed using Hoechst staining (Life Technologies).
N= 5 technical replicates. Significance was determined by one-way ANOVA
with Bonferroni correction. Significance is annotated as less than .0001 (****)
with laminin 521 as control.
Additional file 4: Figure S4. Laminin 521 promotes increased mdx/BL10
differentiation. Cells were freshly isolated from male mdx/BL10 limb muscles
and plated on multiple matrices: laminin 111, laminin 211, laminin 521, and
growth factor reduced Matrigel. MHC area quantification shows a trend
towards increased differentiation on laminin 521 compared to other
substrates. N = 3 technical replicates per substrate. Differences were not
found to be statistically different by one-way ANOVA and Bonferroni
correction.
Additional file 5: Figure S5. Quantification of protein coating for various
ECM proteins. Laminin 111, laminin 211, laminin 521, and gelatin coat similarly,
while Matrigel is coated at a higher amount. N= 12 technical replicates. Data
is presented as mean with error bars representing standard deviation. Statistics
determined by one-way ANOVA with Bonferroni correction. Significance is
annotated as less than .001 (***) using laminin 521 as control.
Additional file 6: Figure S6. Cell counts for freshly isolated and expanded
myoblasts reveal similar cell adherence across all matrices. (A) Cell counts from
freshly isolated Dba, BL6, and BL10 cells 5 days post isolation show similar cell
adherence on all matrices. (B) Cell counts for Dba, BL6, and BL10 myoblasts
after passage 8 (8 h post plating) reveal similar cell adherence on all matrices
following long-term culture. N= 3 biological replicates (1 each for BL6, Bl10,
and Dba). Differences were not found to be statistically different by one-way
ANOVA and Bonferroni correction. Mean column includes standard deviation
values.
Abbreviations
ECM: Extracellular matrix; FACS: Fluorescent-activated cell sorting; FN: Fibronectin;
GFR-MG: Growth factor reduced Matrigel; IPSC: Induced pluripotent stem cell;
LAM: Laminin; MG: Matrigel; MHC: Myosin heavy chain; SC: Satellite cell
Acknowledgements
The project was supported by the MDA Bridge to Industry Grant (#293738 to
CMP, REA, and PRA). We would like to thank Ken Wertman for scientific
guidance and administrative support.
Availability of data and materials
The datasets used and/or analyzed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
CP conceived the study, carried out the cellular experiments, analyzed the
data, and drafted the manuscript. VB, RA, and PA conceived the study,
participated in its design and coordination, and helped to draft the
manuscript. JP conceived the study and carried out the cellular experiments.
EP carried out the immunohistological studies and helped to draft the
manuscript. MP participated in the design of the study and helped to draft
the manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Ethics approval
All studies involving mice were conducted in accordance with the IACUC
protocols approved by the University of Arizona IACUC (11-268). The human
cells used in the submission were obtained through a commercial source,
Asterand Bioscience. The cells were obtained with approval of the
FederalWide Assurance (# IRB00003411).
Author details
1Discovery Biology, Tucson Innovation Center, Icagen, Oro Valley, AZ 85755,
USA. 2Discovery Biology, Tucson Innovation Center, Sanofi, Oro Valley, AZ
85755, USA. 3School of Animal and Comparative Biomedical Sciences,
University of Arizona, Tucson, AZ 85721, USA.
Received: 11 December 2015 Accepted: 1 December 2016
References
1. Zammit PS, Relaix F, Nagata Y, Ruiz AP, Collins CA, Partridge TA, et al. Pax7
and myogenic progression in skeletal muscle satellite cells. J Cell Sci. 2006;
119(Pt 9):1824–32. doi:10.1242/jcs.02908.
2. Cooper RN, Tajbakhsh S, Mouly V, Cossu G, Buckingham M, Butler-Browne
GS. In vivo satellite cell activation via Myf5 and MyoD in regenerating
mouse skeletal muscle. J Cell Sci. 1999;112(Pt 17):2895–901.
3. Naidu PS, Ludolph DC, To RQ, Hinterberger TJ, Konieczny SF. Myogenin and
MEF2 function synergistically to activate the MRF4 promoter during
myogenesis. Mol Cell Biol. 1995;15(5):2707–18.
4. Wright WE, Sassoon DA, Lin VK. Myogenin, a factor regulating myogenesis,
has a domain homologous to MyoD. Cell. 1989;56(4):607–17.
5. Yao CC, Ziober BL, Sutherland AE, Mendrick DL, Kramer RH. Laminins
promote the locomotion of skeletal myoblasts via the alpha 7 integrin
receptor. J Cell Sci. 1996;109(Pt 13):3139–50.
6. Johansson S, Svineng G, Wennerberg K, Armulik A, Lohikangas L.
Fibronectin-integrin interactions. Front Biosci. 1997;2:d126–46.
7. Disatnik MH, Rando TA. Integrin-mediated muscle cell spreading. The role of
protein kinase c in outside-in and inside-out signaling and evidence of
integrin cross-talk. J Biol Chem. 1999;274(45):32486–92.
8. Bentzinger CF, Wang YX, von Maltzahn J, Soleimani VD, Yin H, Rudnicki MA.
Fibronectin regulates Wnt7a signaling and satellite cell expansion. Cell Stem
Cell. 2013;12(1):75–87. doi:10.1016/j.stem.2012.09.015.
9. Le Grand F, Jones AE, Seale V, Scime A, Rudnicki MA. Wnt7a activates the
planar cell polarity pathway to drive the symmetric expansion of satellite
stem cells. Cell Stem Cell. 2009;4(6):535–47. doi:10.1016/j.stem.2009.03.013.
10. Patton BL, Connoll AM, Martin PT, Cunningham JM, Mehta S, Pestronk A,
et al. Distribution of ten laminin chains in dystrophic and regenerating
muscles. Neuromuscul Disord. 1999;9(6-7):423–33.
11. Tiger CF, Champliaud MF, Pedrosa-Domellof F, Thornell LE, Ekblom P,
Gullberg D. Presence of laminin alpha5 chain and lack of laminin alpha1
chain during human muscle development and in muscular dystrophies.
J Biol Chem. 1997;272(45):28590–5.
Penton et al. Skeletal Muscle  (2016) 6:44 Page 15 of 16
12. Talts JF, Andac Z, Gohring W, Brancaccio A, Timpl R. Binding of the G
domains of laminin alpha1 and alpha2 chains and perlecan to heparin,
sulfatides, alpha-dystroglycan and several extracellular matrix proteins.
EMBO J. 1999;18(4):863–70. doi:10.1093/emboj/18.4.863.
13. Talts JF, Sasaki T, Miosge N, Gohring W, Mann K, Mayne R, et al. Structural
and functional analysis of the recombinant G domain of the laminin alpha4
chain and its proteolytic processing in tissues. J Biol Chem. 2000;275(45):
35192–9. doi:10.1074/jbc.M003261200.
14. Hirosaki T, Mizushima H, Tsubota Y, Moriyama K, Miyazaki K. Structural
requirement of carboxyl-terminal globular domains of laminin alpha 3 chain
for promotion of rapid cell adhesion and migration by laminin-5. J Biol
Chem. 2000;275(29):22495–502. doi:10.1074/jbc.M001326200.
15. Yu H, Talts JF. Beta1 integrin and alpha-dystroglycan binding sites are
localized to different laminin-G-domain-like (LG) modules within the laminin
alpha5 chain G domain. Biochem J. 2003;371(Pt 2):289–99. doi:10.1042/
BJ20021500.
16. Domogatskaya A, Rodin S, Tryggvason K. Functional diversity of
laminins. Annu Rev Cell Dev Biol. 2012;28:523–53. doi:10.1146/
annurev-cellbio-101011-155750.
17. Motohashi N, Asakura Y, Asakura A. Isolation, culture, and transplantation of
muscle satellite cells. J Vis Exp. 2014(86). doi:10.3791/50846.
18. Lagord C, Soulet L, Bonavaud S, Bassaglia Y, Rey C, Barlovatz-Meimon G, et
al. Differential myogenicity of satellite cells isolated from extensor digitorum
longus (EDL) and soleus rat muscles revealed in vitro. Cell Tissue Res. 1998;
291(3):455–68.
19. Shefer G, Wleklinski-Lee M, Yablonka-Reuveni Z. Skeletal muscle satellite
cells can spontaneously enter an alternative mesenchymal pathway. J Cell
Sci. 2004;117(Pt 22):5393–404. doi:10.1242/jcs.01419.
20. Podleski TR, Greenberg I, Schlessinger J, Yamada KM. Fibronectin delays the
fusion of L6 myoblasts. Exp Cell Res. 1979;122(2):317–26.
21. Wilschut KJ, Haagsman HP, Roelen BA. Extracellular matrix components
direct porcine muscle stem cell behavior. Exp Cell Res. 2010;316(3):341–52.
doi:10.1016/j.yexcr.2009.10.014.
22. Mitchell PO, Mills T, O'Connor RS, Kline ER, Graubert T, Dzierzak E, et al.
Sca-1 negatively regulates proliferation and differentiation of muscle cells.
Dev Biol. 2005;283(1):240–52. doi:10.1016/j.ydbio.2005.04.016.
23. Przewozniak M, Czaplicka I, Czerwinska AM, Markowska-Zagrajek A,
Moraczewski J, Streminska W, et al. Adhesion proteins—an impact on
skeletal myoblast differentiation. PLoS One. 2013;8(5):e61760. doi:10.1371/
journal.pone.0061760.
24. Brzoska E, Bello V, Darribere T, Moraczewski J. Integrin alpha3 subunit
participates in myoblast adhesion and fusion in vitro. Differentiation. 2006;
74(2-3):105–18. doi:10.1111/j.1432-0436.2005.00059.x.
25. Sastry SK, Lakonishok M, Thomas DA, Muschler J, Horwitz AF. Integrin alpha
subunit ratios, cytoplasmic domains, and growth factor synergy regulate
muscle proliferation and differentiation. J Cell Biol. 1996;133(1):169–84.
26. Sastry SK, Lakonishok M, Wu S, Truong TQ, Huttenlocher A, Turner CE et al.
Quantitative changes in integrin and focal adhesion signaling regulate
myoblast cell cycle withdrawal. J Cell Biol. 1999;144(6):1295-309.
27. Urciuolo A, Quarta M, Morbidoni V, Gattazzo F, Molon S, Grumati P, et al.
Collagen VI regulates satellite cell self-renewal and muscle regeneration. Nat
Commun. 2013;4:1964. doi:10.1038/ncomms2964.
28. Trensz F, Lucien F, Couture V, Sollrald T, Drouin G, Rouleau AJ, et al. Increased
microenvironment stiffness in damaged myofibers promotes myogenic
progenitor cell proliferation. Skelet Muscle. 2015;5:5. doi:10.1186/s13395-015-0030-1.
29. Lacraz G, Rouleau AJ, Couture V, Sollrald T, Drouin G, Veillette N, et al. Increased
stiffness in aged skeletal muscle impairs muscle progenitor cell proliferative
activity. PLoS One. 2015;10(8):e0136217. doi:10.1371/journal.pone.0136217.
30. Engler AJ, Sen S, Sweeney HL, Discher DE. Matrix elasticity directs stem cell
lineage specification. Cell. 2006;126(4):677–89. doi:10.1016/j.cell.2006.06.044.
31. Engler AJ, Griffin MA, Sen S, Bonnemann CG, Sweeney HL, Discher DE.
Myotubes differentiate optimally on substrates with tissue-like stiffness:
pathological implications for soft or stiff microenvironments. J Cell Biol.
2004;166(6):877–87. doi:10.1083/jcb.200405004.
32. Rossi CA, Flaibani M, Blaauw B, Pozzobon M, Figallo E, Reggiani C, et al. In
vivo tissue engineering of functional skeletal muscle by freshly isolated
satellite cells embedded in a photopolymerizable hydrogel. FASEB J. 2011;
25(7):2296–304. doi:10.1096/fj.10-174755.
33. Hughes CS, Postovit LM, Lajoie GA. Matrigel: a complex protein mixture
required for optimal growth of cell culture. Proteomics. 2010;10(9):1886–90.
doi:10.1002/pmic.200900758.
34. Ringelmann B, Roder C, Hallmann R, Maley M, Davies M, Grounds M, et al.
Expression of laminin alpha1, alpha2, alpha4, and alpha5 chains, fibronectin,
and tenascin-C in skeletal muscle of dystrophic 129ReJ dy/dy mice. Exp Cell
Res. 1999;246(1):165–82. doi:10.1006/excr.1998.4244.
35. Tiger CF, Gullberg D. Abscence of laminin alpha1 chain in the skeletal
muscle of dystrophic dy/dy mice. Muscle Nerve. 1997;20(12):1515–24.
36. Goudenege S, Lamarre Y, Dumont N, Rousseau J, Frenette J, Skuk D, et al.
Laminin-111: a potential therapeutic agent for Duchenne muscular
dystrophy. Mol Ther. 2010;18(12):2155–63. doi:10.1038/mt.2010.165.
37. Gawlik KI, Oliveira BM, Durbeej M. Transgenic expression of laminin alpha1
chain does not prevent muscle disease in the mdx mouse model for
Duchenne muscular dystrophy. Am J Pathol. 2011;178(4):1728–37. doi:10.
1016/j.ajpath.2010.12.030.
38. Law PK, Goodwin TG, Fang Q, Deering MB, Duggirala V, Larkin C, et al. Cell
transplantation as an experimental treatment for Duchenne muscular
dystrophy. Cell Transplant. 1993;2(6):485–505.
39. Law PK, Goodwin TG, Fang Q, Duggirala V, Larkin C, Florendo JA, et al.
Feasibility, safety, and efficacy of myoblast transfer therapy on Duchenne
muscular dystrophy boys. Cell Transplant. 1992;1(2-3):235–44.
40. Law PK, Goodwin TG, Fang QW, Chen M, Li HJ, Florendo JA, et al.
Myoblast transfer therapy for Duchenne muscular dystrophy. Acta
Paediatr Jpn. 1991;33(2):206–15.
41. Mendell JR, Kissel JT, Amato AA, King W, Signore L, Prior TW, et al. Myoblast
transfer in the treatment of Duchenne's muscular dystrophy. N Engl J Med.
1995;333(13):832–8. doi:10.1056/NEJM199509283331303.
42. Montarras D, Morgan J, Collins C, Relaix F, Zaffran S, Cumano A, et al. Direct
isolation of satellite cells for skeletal muscle regeneration. Science. 2005;
309(5743):2064–7. doi:10.1126/science.1114758.
43. Grefte S, Vullinghs S, Kuijpers-Jagtman AM, Torensma R, Von den Hoff JW.
Matrigel, but not collagen I, maintains the differentiation capacity of muscle
derived cells in vitro. Biomed Mater. 2012;7(5):055004. doi:10.1088/1748-
6041/7/5/055004.
44. Kanisicak O, Mendez JJ, Yamamoto S, Yamamoto M, Goldhamer DJ.
Progenitors of skeletal muscle satellite cells express the muscle
determination gene. MyoD Dev Biol. 2009;332(1):131–41. doi:10.1016/j.ydbio.
2009.05.554.
45. Wilschut KJ, van Tol HT, Arkesteijn GJ, Haagsman HP, Roelen BA. Alpha 6
integrin is important for myogenic stem cell differentiation. Stem Cell Res.
2011;7(2):112–23. doi:10.1016/j.scr.2011.05.001.
46. Jarocha D, Stangel-Wojcikiewicz K, Basta A, Majka M. Efficient myoblast
expansion for regenerative medicine use. Int J Mol Med. 2014;34(1):83–91.
doi:10.3892/ijmm.2014.1763.
47. Salani S, Donadoni C, Rizzo F, Bresolin N, Comi GP, Corti S. Generation of
skeletal muscle cells from embryonic and induced pluripotent stem cells as
an in vitro model and for therapy of muscular dystrophies. J Cell Mol Med.
2012;16(7):1353–64. doi:10.1111/j.1582-4934.2011.01498.x.
48. Hosoyama T, McGivern JV, Van Dyke JM, Ebert AD, Suzuki M. Derivation of
myogenic progenitors directly from human pluripotent stem cells using a
sphere-based culture. Stem Cells Transl Med. 2014;3(5):564–74.
doi:10.5966/sctm.2013-0143.
49. Awaya T, Kato T, Mizuno Y, Chang H, Niwa A, Umeda K, et al. Selective
development of myogenic mesenchymal cells from human embryonic and
induced pluripotent stem cells. PLoS One. 2012;7(12):e51638. doi:10.1371/
journal.pone.0051638.
50. Maffioletti SM, Gerli MF, Ragazzi M, Dastidar S, Benedetti S, Loperfido M,
et al. Efficient derivation and inducible differentiation of expandable skeletal
myogenic cells from human ES and patient-specific iPS cells. Nat Protoc.
2015;10(7):941–58. doi:10.1038/nprot.2015.057.
Penton et al. Skeletal Muscle  (2016) 6:44 Page 16 of 16
